Vitabiotics expands international capabilities with Hikma partnership

Vitabiotics has formed a new distribution partnership with Hikma Pharmaceuticals that will expand international access to its products.

Under the terms of the agreement, Hikma will be granted exclusive rights to register, market, distribute and sell Vitabiotics' Liverel, Diabetone-PN, Cardioace, Immunace and Dopative brands in 15 key Middle East and North Africa (MENA) markets.

Additionally, Hikma will have the exclusive rights to market, distribute and sell the full Vitabiotics product range – which includes key products such as Osteocare, Feroglobin, Menopace, Pregnacare and Perfectil – in in five of these markets.

The partnership aims to work in cooperation with existing Vitabiotics partners in the MENA territories in order to broaden sales and distribution coverage.

Hikma Pharmaceuticals is a fast-growing multinational pharmaceutical group, with a strong presence in MENA territories. This makes it a strategically advantageous partner for Vitabiotics, the UK's largest nutraceuticals and vitamin company.

Dr Kartar Lavani, chief executive officer of Vitabiotics, said: "The MENA region is of key strategic importance for Vitabiotics' growth and we plan to build strongly on the brand leading position we have already established in many markets across the region."